The Pennsylvania Supreme Court held in 700 Pharmacy v. Bureau of Workers’ Compensation Fee Review Hearing Office (State Workers’ Insurance Fund), Nos. 97-101 MAP 2024 (decided June 16, 2026), that the workers compensation anti-referral statute does not bar a physician from referring an injured worker to a pharmacy in which the physician holds a financial interest. Justice Mundy, writing for a 5-2 majority, read Section 306(f.1)(3)(iii) of the Workers’ Compensation Act, 77 P.S. section 531(3)(iii), to reach only the eight services it names; the phrase “goods or services” is not a catchall. The decision reversed the Commonwealth Court and remanded the five consolidated fee-review disputes, in which the insurer had stipulated the prescribing physicians had a financial interest in the dispensing pharmacy and refused payment on that basis.
For reserve buyers, the holding removes a defense. Where a Pennsylvania payer suspended or denied a pharmacy bill on the theory that the prescription originated in a prohibited self-referral, that theory is no longer available under the statute as written.
Who it affects
This affects self-insured employers, public entities, health systems, universities, and captives carrying Pennsylvania workers compensation exposure. The risk concentrates in programs with older lost-time claims, physician-directed medication patterns, pain-management disputes, and pharmacy bills sitting in fee review or bill-review suspense. It also reaches third-party administrator oversight: if a claim file treats a pharmacy bill as non-payable because the prescriber had a financial relationship with the pharmacy, that denial logic now needs a Pennsylvania-specific review before the next valuation.
What the court said
The majority applied plain-language statutory construction. Section 306(f.1)(3)(iii) makes it unlawful for a provider to refer a person “for laboratory, physical therapy, rehabilitation, chiropractic, radiation oncology, psychometric, home infusion therapy or diagnostic imaging, goods or services” where the provider has a financial interest. The court held that “goods or services” attaches to those enumerated categories rather than sweeping in everything else; prescription drugs and professional pharmaceutical services are not on the list. The majority reinforced the point with structure: the General Assembly expressly named “drugs and professional pharmaceutical services” in a neighboring provision, Section 306(f.1)(3)(vi), but omitted them from the self-referral bar in subsection (iii). Justices Wecht and McCaffery dissented, reading the provision against its cost-containment purpose and arguing the financial relationship at issue is exactly what the statute should reach.
The split matters for reserves in two ways. It is the law today, so Pennsylvania claims should be reserved as the majority applied it on June 16. But the majority also told the legislature how to change it; the opinion notes the General Assembly “is free” to add pharmaceutical services to the bar and “merely recognizes it has so far failed” to do so. That is a roadmap to a future amendment, which is why this is a watch item rather than a permanent reset.
The reserve mechanism: pharmacy severity, then case adequacy
The lever is medical severity flowing into workers compensation IBNR and medical development; the second-order effect is case-reserve adequacy. This is not a frequency story. The ruling creates no new injuries. It raises the expected cost of known claims by retiring a denial assumption embedded in pharmacy review, and it does so in a channel where the unit economics are already steep.
The size of the lever is the dispensing channel itself. WCRI finds that physician-dispensed drugs cost, on average, between 60 percent and more than 300 percent more than the identical medication filled at retail, and that in states permitting the practice it can run 20 to 45 percent of total workers compensation drug spend. The markup is structural: commonly dispensed drugs get repackaged under new National Drug Codes that carry a higher average wholesale price than the original manufacturer’s. A self-referral pathway to a financially affiliated pharmacy is the same economic engine wearing a different label, and 700 Pharmacy leaves it unobstructed in Pennsylvania.
Pennsylvania is an expensive pharmacy state to begin with, which compounds the exposure. WCRI’s CompScope benchmarks put prescription payments per claim in Pennsylvania among the highest of the study states, and the cost base is moving the wrong way: medical payments per claim rose 11 percent in 2025, as we covered in the 2026 CompScope Pennsylvania read. The pricing dispute underneath this is unresolved separately from self-referral; the Commonwealth Court has questioned whether Red Book average wholesale price is a reliable basis for setting Pennsylvania workers compensation drug prices, and a related average-wholesale-price fee dispute is still pending. A payer that loses both the self-referral defense and the AWP-discount argument is exposed on price and on channel at the same time.
The channel-mix point is where the severity actually lives. WCRI’s work on dispensing channels shows delivery pharmacies and physician dispensing dominating dermatological prescription payments, with per-prescription costs running well above retail; we walked through that channel-mix severity variable in the delivery-pharmacy dermatological cost piece. If Pennsylvania open claims carried denied or suspended bills from these high-markup channels and those bills now become payable after fee review, paid medical development can emerge faster than the prior triangle implied. From reviewing self-insured workers compensation triangles, the signal is rarely the legal theory alone. It is whether bill-review savings were treated as permanent and baked into open-claim adequacy.
The immediate diagnostic is the Pennsylvania pharmacy slice of the medical triangle. Do not blend it into a countrywide medical-trend factor if Pennsylvania is large enough to move the estimate. Compare denied, suspended, and fee-review pharmacy bills on open Pennsylvania claims against the current case reserve. If those bills were held out of the reserve estimate, the next valuation may need an explicit case reserve strengthening adjustment rather than a broad severity load: the triangle will show adverse development, but the operational cause is a change in what the file now expects to pay.
The call
Directionally, this pushes Pennsylvania workers compensation pharmacy cost and medical severity up, not down, for programs that had been leaning on the self-referral defense, and it widens the gap between Pennsylvania and states moving the other way. The contrast is sharp: Florida’s First DCA went the opposite direction, ruling that physicians are not pharmacists and removing a 171 percent dispensing markup from its system, while the federal FECA program cut drug spend 82 percent by restructuring its PBM. Pennsylvania just moved against that grain. The exposure is concentrated, not systemic: it lands hardest on mature lost-time claims with physician-directed pharmacy patterns where the denial was the only thing holding the reserve down, and it is bounded by how much of a given program’s Pennsylvania pharmacy spend actually ran through self-referred, financially affiliated channels. The effect could prove temporary if the General Assembly amends the statute, which the majority all but invited; until it does, the conservative posture is to treat the defense as gone.
What to watch: a Pennsylvania legislative response adding pharmaceutical services to the self-referral bar; the pending Red Book AWP fee-review litigation, which governs the price even where the referral is now lawful; and your own emergence on the Pennsylvania pharmacy slice over the next two to four quarters. Put three items on the next reserve-study agenda. First, confirm Pennsylvania pharmacy payments and denied bills are reviewed separately from the rest of workers compensation medical. Second, identify open Pennsylvania claims with physician-directed pharmacy bills in denial, suspense, or fee review. Third, request a sensitivity that assumes those bills become payable unless another statutory defense applies. The case-reserve review should not wait for a legislative fix that may not come.
Sources
- 700 Pharmacy v. Bureau of Workers’ Compensation Fee Review Hearing Office (State Workers’ Insurance Fund), Nos. 97-101 MAP 2024, Pennsylvania Supreme Court majority opinion (June 16, 2026)
- Pennsylvania Supreme Court dissenting opinion, 700 Pharmacy consolidated appeals (June 16, 2026)
- WCRI: “Physician Dispensing in Workers’ Comp: A Costly Loophole, and How to Close It” (60% to 300% markup; 20% to 45% of drug spend)
- Healthesystems: Pennsylvania Workers’ Comp Trends (CompScope prescription payment per claim; Red Book AWP)
- myMatrixx, “Pennsylvania Supreme Court Decides Workers’ Comp Provider Self-Referral Case”
- Insurance Journal, “Pa. Supreme Court: Workers’ Comp Self-Referral Law Does Not Apply to Pharmacies” (June 17, 2026)